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Type 2 diabetes (T2D) is among the most challenging health issues of the 21st century and is associated
with an alarming rise in the incidence. The Arab population is no exception to this trend. The pathophys-
iological processes that lead to development of T2D are still unclear, however impairment in insulin
secretion and/or action is clearly indicated. T2D is a complex disease with susceptibility being governed
by the interaction of multiple genetic and environmental effects. Previous studies indicated that variants
in genes encoding the pancreatic b-cell K+ATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) are
associated with type 2 diabetes. The common Pro12Ala polymorphism in peroxisome proliferator-acti-
vated receptor-c gene (PPAR-c) was conﬁrmed in several studies to be associated with type 2 diabetes
as well. More recently, studies reported variants within a novel gene, TCF7L2, as a putative susceptibility
gene for type 2 diabetes across many ethnic backgrounds around the world. However, studies to date in
Arab cohorts remain limited.
 2009 International Journal of Diabetes Mellitus Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.The association of type 2 diabetes with the P12A polymorphism
of the peroxisome proliferator-activated receptor gene (PPAR-c)
has been established in several populations [1]. While many vari-
ants have been identiﬁed in this gene, the most prevalent and best
studied is the P12A polymorphism. There is considerable interpop-
ulation variance in the incidence of the risk allele (P12). This ranges
in frequency from a high of 0.96–0.98 in populations including the
Japanese, Chinese, and African Americans to 0.91 in Pima Indians
and a low of 0.81 in the Finnish population [2]. In the ﬁrst Arab
study of the P12A polymorphism of PPAR-c, we observed the P,
or risk allele, frequency to be 0.974 and 0.968 in type 2 diabetic
and control subjects, respectively and was not statistically signiﬁ-
cant [3]. However, given the very high incidence of the P allele in
this population, the study size was extremely underpowered. The
high incidence of the P allele in the Saudi population was con-
ﬁrmed by a neonatal sample set in which frequency of this allele
was found to be 0.957 [3]. Clearly the risk allele frequency of the
Saudi population was comparable to the Japanese, Chinese, and
African Americans and among the highest observed.
Insulin is secreted from pancreatic b-cells in response to nutri-
ents, predominantly glucose but also fatty acids and some amino
acids. Glucose metabolism is increased in response to rising cellu-
lar glucose levels and results in the production of ATP from ADP.
Increased cytosolic ATP:ADP ratios trigger closure of KATP chan-
nels and membrane depolarization via reduced K+ efﬂux and sub-Mellitus Published by Elsevier Ltd.
+966 12055171.
).sequent activation of voltage gated calcium channels giving rise to
transient increases in intracellular calcium. This in turn induces the
exocytosis of insulin-containing granules [4]. Whilst voltage-gated
and calcium-activated potassium channels are involved in mem-
brane repolarisation, KATP channels transduce glucose-mediated
metabolic signals into electrical activity which modulates insulin
secretion. The KATP channel consists of two types of subunit: an
inward-rectiﬁer potassium channel subunit (Kir6.2) [5,6], and a
sulfonylurea receptor subunit (SUR) [7]. The KATP channel is made
of 4 Kir6.2 subunits coupled to four high-afﬁnity SUR subunits
[5,8–10]. The Kir6.2 subunit is encoded by KCNJ11, and the SUR
subunit is encoded by ABCC8. Both genes reside adjacent to one an-
other on chromosome 11. The four Kir6.2 subunits form the pore of
the channel through which K+ passes and also contain the ATP-
binding sites. The four SUR subunits modulate the activity of the
channel and contain the binding site of sulfonylurea drugs [7].
Mutations in either KCNJ11 or ABBC8 can dramatically affect KATP
channel activity, leading to either increased or decreased insulin
release [11–15].
Common polymorphisms of ABCC8 and KCNJ11, particularly the
E23K variant, have been associated with type 2 diabetes in several
populations including non-European populations [16–26]. Current
status of the E23K polymorphism and the implications for type 2
diabetes is discussed by Riedel et al. [27]. Direct effects of polymor-
phisms in ABCC8 (exon 16-3t/c, exon 18 C/T) have not been dem-
onstrated, however, a functional role is proposed for the E23K
variant of KCNJ11 which is reported to stimulate increased pancre-
atic b-cell activity, thus increasing the ATP threshold for insulin
secretion [18]. The E23K variant of KCNJ11 results from a G? AOpen access under CC BY-NC-ND license.
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casian populations showed that KK homozygosity had a stronger
association with type 2 diabetes relative to EK heterozygosity or
EE wild-type homozygosity [19]. We conducted the only study
investigating an association between T2D risk and the E23K poly-
morphism of KCNJ11 in an Arab population to date. Our study con-
ﬁrmed in the Saudi population, association of the E23K allele with
type 2 diabetes as seen in several other populations [16–26].
Whilst association with the K allele was evident, sample size did
not establish whether the risk was recessive in nature and driven
by the KK genotype. Other studies have indicated that association
could be driven by KK homozygosity [22], however even with the
high consanguinity rate in the Saudi population (60%) [28] where
recessive effects are likely to be ampliﬁed, this was not readily
evident.
Researchers at Decode Genetics reported strong association be-
tween variants in a novel susceptibility gene called TCF7L2 and
type 2 diabetes in Icelandic diabetic patients [29]. TCF7L2 encodes
the transcription factor 7-like 2 [30]. The overexpression of this
gene in human pancreatic b-cells was shown to associate with im-
paired insulin secretion both in vivo and in vitro [31]. This gene re-
ceived attention from many research groups following this report,
and similar studies were replicated in samples from several popu-
lations. Many studies have conﬁrmed the original ﬁndings. Sub-
stantial association has been conﬁrmed between variants in
TCF7L2 and type 2 diabetes among broad ethnic backgrounds,
including for example populations of UK [32], Dutch [33], Amish
[34], Finnish [35], Swedish [36], French [37], and US [38,39], Indian
[40], and Japanese [41] origin. It is noteworthy that, as in the origi-
nal report, there was clear evidence of a gene dosage effect, such
that the 10% of individuals with two copies of the susceptibility al-
lele were at almost twice the risk of developing type 2 diabetes
compared to those with only one copy [32,42,43]. Very recently,
lack of association between variants in TCF7L2 and type 2 diabetes
has been reported in Pima Indians and Chinese diabetics [43,44]. In
another association study performed in Arabs [45], the authors re-
ported only a marginal association between rs12255372 and type 2
diabetes risk and no association with rs7903146.
Variants in TCF7L2 have been strongly associated with type 2
diabetes risk [46]. In a Saudi cohort rs12255372 and rs7903146
were not or only weakly associated with T2D. Several studies from
non-European ethnic backgrounds have reported a positive associ-
ation between TCF7L2 variants and T2D. The ﬁrst, an Indian study,
investigated 3 TCF7L2 variants (rs7903146, rs12255372, and
rs4506565) and reported signiﬁcant association between all three
SNPs and T2D [40]. In a Japanese study, four TCF7L2 SNPs were ex-
plored (rs12255372, rs7903146, rs7901695 and rs11196205) and
all four SNPs were found to be signiﬁcantly associated with T2D,
with rs12255372 showing the strongest association [41]. The third
study was conducted by Cauchi et al. on Moroccans [46]. Signiﬁ-
cant association between rs7903146 variant of TCF7L2 and T2D
risk in this population was concluded. Additionally, positive asso-
ciation was also reported on Indian Asians [47,48], Pakistanis
[49], and Afro-Caribbeans [48]. More recently, a surprising lack of
association between TCF7L2 variants and type 2 diabetes was inde-
pendently reported in two non-European populations including
Chinese [43], Pima Indians [44] and in respect to rs7903146 in
Emirati Arabs [45]. In a meta analysis conducted by Cauchi et al.,
the authors reviewed the association of rs7903146 variant with
T2D risk by looking at 27 original published association studies
(including their own), the authors arrived at a pooled OR of 1.46.
There was no overlap between the overall OR and CIs of this
meta-analysis and the upper CI of the Saudi cohort (1.27) [50].
However, there is an overlap with three studies included in this
meta-analysis [38,48,51]. Therefore, even though signiﬁcant asso-
ciation was not indicated in the Saudi cohort, a weak associationcould not be ruled out and justiﬁes a larger replication study in
Arabs.
Given the limited studies conducted in Arabs to date, two points
are clear. Firstly results indicate differences in Arab populations in
relation to genetic risk for T2D. Secondly, data presented in the lit-
erature to date clearly demand replication studies, ideally with lar-
ger numbers to conﬁrm ﬁndings reported thus far. Similarly,
further T2D association studies either candidate gene based or gen-
ome-wide are warranted in Arabs and may reveal novel risk loci for
this important global disease.References
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